Document is current

Any future updates will be listed below

A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients

Crossref DOI link: https://doi.org/10.1186/s13045-016-0266-1

Published Online: 2016-04-12

Published Print: 2016-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark